Get the Stockscreener App
1.28
3.23%
0.04
After Hours:
1.35
0.07
+5.47%
Ventyx Biosciences Inc stock is traded at $1.28, with a volume of 1.01M.
It is up +3.23% in the last 24 hours and up +5.79% over the past month.
Ventyx Biosciences Inc is a clinical-stage biopharmaceutical company focused on advancing new therapies for millions of patients living with inflammatory diseases and autoimmune, and neurodegenerative disorders. The company is developing a pipeline of novel small-molecule product candidates to address a range of inflammatory diseases. Its product candidate VTX958 is an oral, selective clinical-stage tyrosine kinase type 2 (TYK2) inhibitor designed to inhibit TYK2 without detectable inhibition of other Janus kinase (JAK) isoforms, which avoids toxicities associated with broader JAK inhibition and, thus, other JAK inhibitors.
See More
Previous Close:
$1.24
Open:
$1.24
24h Volume:
1.01M
Relative Volume:
0.95
Market Cap:
$83.97M
Revenue:
-
Net Income/Loss:
$-192.96M
P/E Ratio:
-0.3879
EPS:
-3.3
Net Cash Flow:
$-167.04M
1W Performance:
+8.47%
1M Performance:
+5.79%
6M Performance:
-46.44%
1Y Performance:
-66.62%
1-Day Range:
$1.225
$1.32
1-Week Range:
$1.14
$1.32
52-Week Range:
$0.783
$5.66
Ventyx Biosciences Inc Stock (VTYX) Company Profile
Name
Ventyx Biosciences Inc
Sector
Industry
Phone
(858) 945-2393
Address
12790 EL CAMINO REAL, SUITE 200, SAN DIEGO
Compare VTYX with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
VTYX
Ventyx Biosciences Inc
|
1.28 | 83.97M | 0 | -192.96M | -167.04M | -3.30 |
|
VRTX
Vertex Pharmaceuticals Inc
|
503.50 | 126.09B | 11.02B | -535.60M | -978.00M | -2.20 |
|
REGN
Regeneron Pharmaceuticals Inc
|
568.91 | 64.01B | 14.20B | 4.41B | 3.54B | 38.28 |
|
ARGX
Argen X Se Adr
|
629.51 | 36.63B | 2.19B | 833.04M | -1.28B | 12.71 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
257.19 | 30.64B | 2.25B | -278.16M | -42.59M | -2.17 |
|
ONC
Beigene Ltd Adr
|
249.77 | 27.24B | 3.81B | -644.79M | -669.77M | -6.24 |
Ventyx Biosciences Inc Stock (VTYX) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Mar-12-24 | Upgrade | Oppenheimer | Perform → Outperform |
| Mar-12-24 | Upgrade | Wells Fargo | Equal Weight → Overweight |
| Nov-07-23 | Downgrade | H.C. Wainwright | Buy → Neutral |
| Nov-07-23 | Downgrade | Morgan Stanley | Overweight → Equal-Weight |
| Nov-07-23 | Downgrade | Oppenheimer | Outperform → Perform |
| Nov-07-23 | Downgrade | Stifel | Buy → Hold |
| Nov-07-23 | Downgrade | Wells Fargo | Overweight → Equal Weight |
| Jun-14-23 | Resumed | Credit Suisse | Outperform |
| Mar-21-23 | Initiated | Wells Fargo | Overweight |
| Dec-19-22 | Initiated | Goldman | Buy |
| Nov-17-22 | Initiated | Morgan Stanley | Overweight |
| Sep-07-22 | Initiated | Stifel | Buy |
| Sep-01-22 | Initiated | H.C. Wainwright | Buy |
| May-09-22 | Initiated | Credit Suisse | Outperform |
| Mar-31-22 | Initiated | Canaccord Genuity | Buy |
| Feb-01-22 | Initiated | Oppenheimer | Outperform |
| Nov-15-21 | Initiated | Jefferies | Buy |
| Nov-15-21 | Initiated | Piper Sandler | Overweight |
View All
Ventyx Biosciences Inc Stock (VTYX) Latest News
Geode Capital Management LLC Increases Stock Position in Ventyx Biosciences, Inc. (NASDAQ:VTYX) - Defense World
Renaissance Technologies LLC Acquires 310,800 Shares of Ventyx Biosciences, Inc. (NASDAQ:VTYX) - Defense World
Stock Market Recap: Ventyx Biosciences Inc (VTYX) Concludes at 1.15, a -4.96 Surge/Decline - DWinneX
Ventyx Biosciences Inc’s Market Journey: Closing Strong at 1.43, Up 0.70 - DWinneX
Press Release Distribution & PR Platform - ACCESS Newswire
The Psychology of Ventyx Biosciences Inc Inc. (VTYX) Price Performance: Understanding Market Sentiment - investchronicle.com
JPMorgan Chase & Co. Trims Stake in Ventyx Biosciences, Inc. (NASDAQ:VTYX) - Defense World
VTYX FINAL DEADLINE: ROSEN, GLOBAL INVESTOR COUNSEL, Encourages Ventyx Biosciences, Inc. Investors to Secure Counsel Before Important April 30 Deadline in Securities Class ActionVTYX - The Globe and Mail
Trading Day Review: Ventyx Biosciences Inc (VTYX) Loses Momentum, Closing at 1.16 - DWinneX
Ventyx Biosciences Inc [NASDAQ: VTYX] Sees Decrease in Stock Value - knoxdaily.com
Ventyx Biosciences Inc (VTYX) stock analysis: A comprehensive overview - uspostnews.com
Arthralgia Market to Reach New Heights in Growth by 2032, DelveInsight Predicts | Sun Pharma, Bristol-Myers Squibb, UCB Biopharma, Affibody, Ventyx Biosciences, Aclaris Therapeutics, AbbVie, Novartis - The Globe and Mail
VENTYX INVESTOR UPDATE: Ventyx’s (Nasdaq:VTYX) Board is Being Investigated for Insider Trading, Long-term Investors Are Urged to Contact the Firm for Details - ACCESS Newswire
Investors who lost money on Ventyx Biosciences, Inc.(VTYX) should contact Levi & Korsinsky about pending Class ActionVTYX - ACCESS Newswire
Is the Ventyx Biosciences Inc (NASDAQ:VTYX) stock an investment opportunity? - uspostnews.com
Ventyx Biosciences stock hits 52-week low at $0.89 amid market challenges - Investing.com Australia
Ventyx Biosciences stock hits 52-week low at $0.89 amid market challenges By Investing.com - Investing.com South Africa
Is Ventyx Biosciences Inc (NASDAQ: VTYX) Still Trending? - stocksregister.com
Ventyx Biosciences chief scientific officer John Nuss sells $2,019 in shares - Investing.com India
VTYX INVESTOR ALERT: Bronstein, Gewirtz & Grossman LLC Announces that Ventyx Biosciences, Inc. Investors Can Join the Class Action Lawsuit! - ACCESS Newswire
Shareholders that lost money on Ventyx Biosciences, Inc.(VTYX) Urged to Join Class ActionContact Levi & Korsinsky to Learn More - ACCESS Newswire
FINAL DEADLINE REMINDER: The Schall Law Firm Encourages Investors in Ventyx Biosciences, Inc. with Losses of $100,000 to Contact the Firm - ACCESS Newswire
Stock Traders Purchase Large Volume of Call Options on Ventyx Biosciences (NASDAQ:VTYX) - Defense World
Ventyx boosts advisory board with top scientists By Investing.com - Investing.com South Africa
Ventyx boosts advisory board with top scientists - Investing.com
Ventyx Biosciences Expands SAB with Renowned NLRP3 Experts - GlobeNewswire
7 World-Class NLRP3 Experts Join Ventyx as Phase 2 Trials Advance in Parkinson's Disease - Stock Titan
Insiders' US$1.26m Investments In Red Following Ventyx Biosciences' US$11m Dip In Market Value - simplywall.st
Ventyx Biosciences stock hits 52-week low at $1.21 amid market challenges - Investing.com
VTYX Stock Sees Decline of Approximately -9.63% in Last Five Days - knoxdaily.com
Ventyx Biosciences stock hits 52-week low at $1.28 amid market challenges - Investing.com Australia
Ventyx Biosciences Faces Supply Chain Risks Amidst U.S.-China Tensions and Regulatory Challenges - MSN
Ventyx Biosciences stock hits 52-week low at $1.37 amid market challenges - Investing.com Australia
Rhumbline Advisers Acquires 40,813 Shares of Ventyx Biosciences, Inc. (NASDAQ:VTYX) - Defense World
Ventyx Biosciences, Inc. Sued for Securities Law Violations – Investors Should Contact Levi & Korsinsky Before April 30, 2024 to Discuss Your Rights – VTYX - ACCESS Newswire
Ventyx Biosciences Reports 2024 Financial Results and Progress - TipRanks
Levi & Korsinsky Notifies Shareholders of Ventyx Biosciences, Inc.(VTYX) of a Class Action Lawsuit and an Upcoming Deadline - ACCESS Newswire
Ventyx Biosciences stock hits 52-week low at $1.41 amid market challenges - Investing.com India
Ventyx Biosciences stock hits 52-week low at $1.41 amid market challenges By Investing.com - Investing.com South Africa
FINAL DEADLINE IMMINENT: The Schall Law Firm Encourages Investors in Ventyx Biosciences, Inc. with Losses of $100,000 to Contact the Firm - ACCESS Newswire
Class Action Filed Against Ventyx Biosciences, Inc. (VTYX)April 30, 2024 Deadline to JoinContact Levi & Korsinsky - ACCESS Newswire
Ventyx Biosciences Inc Stock (VTYX) Financials Data
Revenue
Net Income
Cash Flow
EPS
0.78%
2.03%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):